Author Archives: Jan Paschal

Zenas BioPharma (ZBIO) upsized its IPO at pricing to 13.24 million shares (13,235,294 shares) – up from 11.76 million shares in the prospectus – and priced its IPO at $17.00 – the mid-point of its $16.00-to-$18.00 price range – to raise $225.0 million on Thursday night, Sept. 12, 2024. At pricing, Zenas BioPharma increased the […]

Bicara Therapeutics (BCAX) increased its IPO’s size at pricing to 17.5 million shares – up from 14.71 million shares – and priced the IPO at $18.00 – the top of its $16.00-to-$18.00 range – to raise $315 million on Thursday night, Sept. 12, 2024. This was the second time that Bicara Therapeutics had upsized its […]

MBX Biosciences (MBX) upsized its IPO to 10.2 million shares – up from 8.5 million shares in the prospectus – and priced the deal at $16.00 – the top of its $14.00-to-$16.00 range – to raise $163.2 million on Thursday night, Sept. 12, 2024. At pricing, MBX Biosciences increased the IPOs size by 20 percent. Shares […]

Galaxy Payroll Group Ltd. (GLXG) of Hong Kong downsized its IPO at pricing – to 1.75 million shares – down from 2.0 million shares in the prospectus – and priced the deal at $4.00, as expected – to raise $7.0 million on Wednesday night, Sept. 11, 2024. Galaxy Payroll’s stock started trading today – Thursday, […]

Bicara Therapeutics (BCAX Proposed), a clinical biotech focused on head and neck squamous cell cancer, increased the size of its IPO to $250 million – up from $200 million initially – in an S-1/A filing after the closing bell on Wednesday, Sept. 11, 2024. The new terms calls for Bicera Therapeutics to offer 14.71 million […]

Bankers priced two small IPOs – Trident Digital Tech Holdings (TDTH) and XCHG Ltd. (XCH) – at or near the low end of their respective price ranges on Monday night, Sept. 9, 2024, to trade today – Tuesday, Sept. 10, 2024 – on the NASDAQ. Here are the pricing details: * Trident Digital Tech Holdings (TDTH) priced its […]

MBX Biosciences (MBX Proposed), a Phase 2 biotech targeting endocrine and metabolic diseases, disclosed the terms for its $127.5 million IPO and launched the deal early today – Monday, Sept. 9, 2024 – for pricing later this week. MBX Biosciences Inc. is offering 8.5 million shares at a price range of $14.00 to $16.00 to […]

Two biotechs – Bicara Therapeutics (BCAX Proposed) and Zenas BioPharma (ZBIO Proposed) – lead the IPO Calendar this week – the week of Sept. 9, 2024 – with plans to raise about $200 million each. Both IPOs are similar in size: Each company plans to offer about 11.8 million shares at a price range of […]

Zenas BioPharma (ZBIO Proposed), a Phase 2/Phase 3 clinical biotech focused on MS and other autoimmune diseases, disclosed the terms for its $199.9 million IPO and launched the deal early today – Friday, Sept. 6, 2024 – for pricing next week. The clinical biotech is offering 11.8 million shares at a price range of $16.00 […]

Cancer biotech Bicara Therapeutics (BCAX Proposed) disclosed the terms for its $200 million IPO early today – Friday, Sept. 6, 2024 – and launched the deal for a NASDAQ debut next week. The biotech, which is targeting head and neck squamous cell cancer, is offering 11.765 million shares at a price range of $16.00 to […]